AlphaStocks
4.4
Weak

IDEXX LABORATORIES INC /DE (IDXX)

Health Care / Health Care Equipment

S&P 500

$579.59

Below average on several measures. Research carefully.

Weak

Score based on 5 of 5 models — high confidence

#740out of 1126 in Health Care

Is IDEXX LABORATORIES INC /DE a Good Investment in 2026?

IDEXX LABORATORIES INC /DE (IDXX) scores 4.4 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates IDEXX LABORATORIES INC /DE as Strong (8/9). However, the Greenblatt Magic Formula model rates it Caution — Top 10% (rank 5%). IDEXX LABORATORIES INC /DE currently trades above its estimated fair value of $365, suggesting limited upside at current prices. IDEXX LABORATORIES INC /DE ranks #740 out of 1126 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E44.3ROE-16.5Market Cap46B

Estimated Fair Value

$364.6559% above

Trading above estimated fair value. P/e of 44x implies high growth expectations.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

8/9

Buffett

Attractive

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Neutral

PEG 3.7 · Stalwart

Greenblatt

Caution

Top 10% (rank 5%)

Frequently Asked Questions

Is IDEXX LABORATORIES INC /DE (IDXX) a good investment?
Based on AlphaStocks' composite analysis, IDEXX LABORATORIES INC /DE (IDXX) scores 4.4 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading above estimated fair value. P/e of 44x implies high growth expectations.
What is IDEXX LABORATORIES INC /DE's Piotroski F-Score?
IDEXX LABORATORIES INC /DE's Piotroski F-Score status is Strong. The raw score is 8/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is IDXX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $365, IDXX appears overvalued. The stock currently trades 59% above its estimated fair value. Trading above estimated fair value. P/e of 44x implies high growth expectations.
How does IDXX compare to other Health Care stocks?
IDEXX LABORATORIES INC /DE ranks #740 out of 1126 stocks in the Health Care sector, placing it in the top 66% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about IDXX?
AlphaStocks evaluates IDXX using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 4.4/10.

Similar Stocks

PARRAZNFTI

Compare IDXX with

IDXX vs PARRIDXX vs AZNIDXX vs FTI

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer